started · updated
Roche launches Xofluza antiviral in Spain
Roche has launched Xofluza in Spain, a prescription oral antiviral medication for the treatment of influenza. It represents the first innovative antiviral for flu approved in Europe in the last 20 years.
The active ingredient, baloxavir marboxil, works by blocking an enzyme required for the virus to multiply, thereby slowing its ability to create new copies. The medication is administered as a single dose and should be taken as soon as possible within 48 hours of symptom onset or after close contact with an infected individual.
Dr. José María Eiros, a professor of Microbiology at the University of Valladolid, noted that early action is critical in treating influenza and that having treatments with different mechanisms of action expands the available tools for managing infections, particularly for vulnerable populations.
Entities
José María Eiros · Roche · Río Hortega University Hospital · University of Valladolid · Xofluza